Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval
SB15 Biosimilar To Eylea Approved Shortly After Firm Agreed Marketing Deal With Samil
Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.
